A Randomized, Double-Blind, Placebo-Controlled Multiple Ascending Dose Study of Intravenous ATYR1923 in Patients With Pulmonary Sarcoidosis
Phase of Trial: Phase I/II
Latest Information Update: 14 Nov 2019
Price : $35 *
At a glance
- Drugs ATYR-1923 (Primary)
- Indications Pulmonary sarcoidosis
- Focus Adverse reactions; Proof of concept
- Sponsors aTyr Pharma
- 14 Nov 2019 According to an aTyr Pharma media release, the company is on track to report an initial interim data analysis focusing on safety data in December.
- 10 Jul 2019 According to an aTyr Pharma media release, the company will host a Key Opinion Leader (KOL) call and webcast that will provide a brief overview of the Company's lead program, ATYR1923 which is currently being evaluated in this study on Thursday, July 18th at 2pm Eastern Time/11am Pacific Time.
- 25 Mar 2019 According to an aTyr Pharma media release, interim results from the study are expected in the fourth quarter of 2019.